Analyst Price Target is C$3.20
▼ -1.23% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Pediapharm in the last 3 months. The average price target is C$3.20, with a high forecast of C$3.20 and a low forecast of C$3.20. The average price target represents a -1.23% upside from the last price of C$3.24.
Current Consensus is
The current consensus among 3 contributing investment analysts is to hold stock in Pediapharm. This rating has held steady since July 2021, when it changed from a Buy consensus rating.
Meredith Corporation, a leading media company for nearly 120 years, produces service journalism that engages audiences with essential, inspiring, and trusted content. Meredith reaches more than 190 million unduplicated American consumers every month, including nearly 95 percent of all U.S. women, across media platforms including digital, video, print, and broadcast television.